Thrombosis

Evidence-based recommendations for the management of antiphospholipid syndrome in adult patients have been issued by EULAR.

Results of a study conducted in primates suggest that a novel protease-activated receptor-4 antagonist could reduce thrombus formation with a lower bleeding risk than other antiplatelet agents.

Treatment with antithrombotic drugs before coronary angiography is associated with excess bleeding in patients with non–ST-segment elevation acute coronary syndromes, study results suggest.

The oral thrombin inhibitor dabigatran may actually increase thrombus formation, suggest the results of a translational study conducted in human arterial plaque and mouse models of blood clotting.

Adanexanet rapidly reverses anti-factor Xa activity in patients with acute major bleeding associated with FXa inhibitors, preliminary results from the ANNEXA-4 study show.

Extended thromboprophylaxis with the direct factor Xa inhibitor betrixaban just fails to show superiority to standard treatment with enoxaparin in acutely ill medical patients.

Data from Taiwan show that asthma is associated with a significant increase in the risk for pulmonary embolism, particularly in patients who experience exacerbations.

Researchers have found that those patients who develop pulmonary embolism have the poorest outcomes among chronic obstructive pulmonary disease patients with venous thromboembolism.

Patients with rheumatoid arthritis have a significantly elevated risk for venous thromboembolism, suggest study findings published in Arthritis Care and Research.

Almost a third of patients treated with protamine for heparin reversal during cardiopulmonary bypass develop antibodies to circulating protamine–heparin complexes, study findings suggest.

Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy.

Findings from two Danish studies have shown that ABO blood type, both alone and in combination with the presence of factor V and prothrombin mutations, is associated with increases in risk for venous thromboembolism.

The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine.

Coagulation tests are warranted in young women undergoing surgery for subclavian vein thrombosis, especially patients with Paget-Schroetter syndrome unrelated to physical activity, say US clinicians.

Patients undergoing oncologic head and neck surgery do not benefit from thromboprophylaxis, report researchers.

In stroke patients in whom intravenous thrombolysis is either contraindicated or has failed, intra-arterial revascularization with cerebral angioplasty and stent placement is an effective and well-tolerated treatment, say Czech researchers.

Administration of cryoprecipitate and tranexamic acid significantly improves the likelihood of survival among seriously injured patients requiring packed red blood cells, suggest results from MATTERS II.

Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say.

Vigorous physical activity is associated with a moderate but transient bleeding risk for hemophilia, resulting in an overall low risk for bleeds, suggests a study of Australian children.

Individuals with rheumatoid arthritis are at an increased risk for venous thromboembolism, research confirms.